Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia

A technology for susceptibility genes and cardiomyopathy, which is applied in the fields of genetic engineering and molecular genetics, can solve the problems of difficult diagnosis, time-consuming and labor-intensive detection costs, and lagging progress, and achieve the goal of multiple detection sites, strong practicability, and low cost Effect

Pending Publication Date: 2019-04-19
GENERAL HOSPITAL OF PLA +1
View PDF11 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the detection of known HCM pathogenic genes can only be carried out by designing primers one by one, PCR amplification, Sanger sequencing, and comparison with reference sequences after determining the target detection genes, which is time-consuming, laborious and expensive; and Molecular genetic diagnosis is often difficult to establish in children without severe mutations in known disease-causing genes, which poses a huge obstacle to genetic counseling and the resolution of many related problems
[0005] Genetic testing is helpful for the differential diagnosis and family screening of HCM, but its application in risk prediction and stratification is still very limited, because HCM genotypes and phenotypes have obvious heterogeneity, most of the reported pathogenic mutations Limited to a few families or sporadic cases, the relationship between genotype and phenotype still needs further study
The second-generation high-throughput sequencing technology (next-generation sequencing technology) has the advantages of fast, accurate, and low cost, and can detect various types of mutations in multiple genes at the same time, and has been widely used in the etiology detection and Molecular genetic diagnosis, however, so far, there have been no high-throughput probes, chips or kits specifically for the detection of causative genes of hereditary cardiomyopathy, making the progress of this disease-related field seriously lagging behind, and it is impossible to clearly identify the disease Due to the low sensitivity of diagnosis, family screening and necessary early intervention and treatment cannot be implemented, which not only brings great pain and heavy economic burden to patients and their families, but also seriously hinders the improvement of the overall quality of the population in my country. Amplitude increase

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia
  • Probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia
  • Probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Embodiment 1 Design and preparation of the probe set of the present invention

[0069] 1. Screening of pathogenic and / or susceptibility genes

[0070] The pathogenic and / or susceptibility genes in this example are MYH7, TNNT2, TPM1, MYBPC3, PRKAG2, TNNI3, MYL3, TTN, MYL2, ACTC1, CSRP3, TNNC1, MYH6, VCL, MYOZ2, JPH2, PLN, CALR3, NEXN, MYPN, ACTN2, LDB3, TCAP, FLNC, MYLK2, CAV3, FHL1, CRYAB, TRIM63, ANKRD1, KLF10, MYOM1, FXN, CASQ2, PDLIM3, MYO6, ACTA1, FHOD3, ELAC2, MRPL3, TRMU, DES, MAP2K1, MAP2K2, GLA, CALM3, BRAF, NDUFAF1, SLC25A3, SLC25A4, NDUFV2, RAF1, SOS1, MTO1, SRI, OBSCN, TACO1, FASTKD2, COX20, COX10, PET100, APOPT1, COX14, COX6B1, AGK, MGME1, GAA, AGL, IDS, PTPN11, KRAS, NRAS, RIT1, SOS2, LZTR1, CBL, SHOC2, NF1, LAMP2, NSD1, CDKN1C, H19, KCNQ1OT1, MRPS16, TSFM, MRPS22, AARS2, MRPL44, GTPBP3, SCO2, COX15, COA5, COA6, ACAD9, MLYCD, SLC22A5, FHL2, LMNA, SCN5A, EYA4, SGCD, ABCC9, TMPO, PSEN1, PSEN2, FKTN, DSG2, RBM20, SDHA, BAG3, LAMA4, PRDM16, GATAD1, DMD, DSP, TN...

Embodiment 2

[0077] Embodiment 2 The composition, preparation and application of the kit of the present invention.

[0078] The kit for detecting the pathogenic and / or susceptibility genes of cardiomyopathy described in this embodiment is to carry out the molecular genetic diagnosis of the individual by detecting the mutation of the above-mentioned 312 pathogenic and / or susceptibility genes Or a kit for morbidity risk prediction.

[0079] 1. The composition of the kit

[0080] The components contained in the kit are: the probe set obtained in Example 1 (160 μL, 150 ng / μL), enrichment buffer (208 μL), hybridization buffer (800 μL), binding buffer (3.2 mL), washing Solution 1 (9mL), rinse solution 2 (45mL), NaOH solution (0.1M, 1mL), Tris-HCl buffer (1M, pH 7.5, 1.2mL), PCR reaction solution (580μL), TE buffer (800μL, 10mM Tris-HCl, 1mM EDTA, adjust the pH to 8.0, and adjust the volume to 500mL with water). Wherein each buffer composition is as follows:

[0081] (1) Enrichment buffer (pe...

Embodiment 3

[0135] Example 3 Clinical diagnosis of the probe set of the present invention

[0136] Molecular genetic diagnosis of 8 patients with hereditary cardiomyopathy and related syndromes using the probe set prepared in Example 1 of the present invention. The patients were clinically diagnosed cardiomyopathy-related diseases in the Department of Cardiovascular Medicine of the hospital. Each patient signed an informed and voluntary agreement, which was approved by the hospital's medical ethics committee.

[0137] The molecular genetic diagnosis of the patient in this example was performed according to the composition, preparation and application steps of the kit described in Example 2. The results of molecular genetic diagnosis are shown in Table 2.

[0138] Table 2 Molecular genetic diagnoses made in patients with hereditary cardiomyopathy and related syndromes

[0139]

[0140]

[0141] 1. Molecular genetic diagnosis of a patient with glycogen storage disease

[0142]The c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a probe group for detecting pathogenic / susceptible genes of hereditary cardiomyopathy / arrhythmia, and provides application of a reagent for detecting pathogenic and / or susceptible genes of the cardiomyopathy in preparing products for diagnosing the cardiomyopathy. The reagent can capture various pathogenic and / or susceptible genes of the cardiomyopathy, and at most 312 related genes can be detected simultaneously. The invention further provides a probe group for detecting the pathogenic and / or susceptible genes of the cardiomyopathy and a kit containing the probe group.The probe group and the kit containing the probe group can be used for molecular genetic diagnosis of a sick individual and family screening of the sick family members, and have important clinical significance to early intervening treatment of the mutation carriers. Meanwhile, the probe group and the kit have the advantages of being high in efficiency, multiple in detection sites, accurate, easy to operate, good in specificity, high in sensitivity, rapid, high in practicability and low in cost.

Description

technical field [0001] The invention relates to the fields of genetic engineering and molecular genetics, in particular to a probe set and kit for individualized capture and sequencing of pathogenic and / or susceptibility genes for detection of cardiomyopathy and / or arrhythmia. Background technique [0002] Cardiomyopathy is a group of complex diseases of the cardiovascular system, which can be limited to the myocardium or part of systemic diseases, that is, diseases with abnormal myocardial morphology and function, excluding all other diseases that can independently cause the above abnormalities. [0003] Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy clinically, characterized by asymmetric hypertrophy of the left and / or right ventricle, the interventricular septum is most often involved, and the main pathology is cardiomyocyte hypertrophy and arrangement disorder feature. The clinical manifestations of HCM are highly heterogeneous, ranging from...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6883C12Q2600/156
Inventor 何昆仑伍建贾倩石金龙赵晓静贾志龙郝丽君赵莉马俊峰孟凡飞
Owner GENERAL HOSPITAL OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products